Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Cash Dwindles to $371K at End of May

Premium

Vermillion had $371,382 in cash at the end of May, the company said in a document filed with the US Securities and Exchange Commission last week.

Due to limited resources resulting from its Chapter 11 filing [see PM 04/02/09], the firm was unable to file an annual report for 2008 and is unable to file quarterly reports. In lieu of those reports, the company is filing monthly operating reports with the US Bankruptcy Court in Delaware.

In its latest such filing, Vermillion reported it began May with $568,930 in cash. It received $7,253 in total receipts, including $2,420 from former employees for insurance coverage under COBRA, and $4,243 as a security deposit refund from the Canadian government. The company recorded no sales for the month.

Meanwhile, the company recorded $204,802 in disbursements, including $158,098 in administrative expenses and $15,655 in net payroll expenses.

As of May 31, Vermillion had $380,970 in cash and cash equivalents, it said in the SEC document. The company's assets totaled more than $9.9 million while its liabilities exceeded $32.8 million.

Last week also, the Bankruptcy Court approved an incentive bonus plan for its three directors [see PM 06/25/09].

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.